Published in Front Immunol on July 23, 2013
Secretion of immunoregulatory cytokines by mesenchymal stem cells. World J Stem Cells (2014) 1.14
Organ-specific and memory treg cells: specificity, development, function, and maintenance. Front Immunol (2014) 1.11
Mesenchymal and induced pluripotent stem cells: general insights and clinical perspectives. Stem Cells Cloning (2015) 0.82
Against Ebola: type I interferon guard risk and mesenchymal stromal cell combat sepsis. J Zhejiang Univ Sci B (2015) 0.82
Optimization of pre-transplantation conditions to enhance the efficacy of mesenchymal stem cells. Int J Biol Sci (2015) 0.81
An engineered multicomponent bone marrow niche for the recapitulation of hematopoiesis at ectopic transplantation sites. J Hematol Oncol (2016) 0.80
Clinical Considerations for Vascularized Composite Allotransplantation of the Eye. J Craniofac Surg (2016) 0.79
Effects of immunosuppressive drugs on viability and susceptibility of adipose- and bone marrow-derived mesenchymal stem cells. Front Immunol (2015) 0.77
Emerging Implications for Extracellular Matrix-Based Technologies in Vascularized Composite Allotransplantation. Stem Cells Int (2015) 0.75
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 12.59
Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views. Stem Cells (2007) 7.57
Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol (2002) 6.92
Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell (2009) 4.75
Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One (2008) 4.37
The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs (2001) 4.31
Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut (2009) 4.06
Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs (2003) 3.70
Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol (2011) 3.65
Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells (2007) 3.49
Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev (2009) 3.43
Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue. J Cell Biochem (2006) 3.11
Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med (2008) 2.97
A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood (2004) 2.90
Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA (2012) 2.85
Stem cell transplantation: the lung barrier. Transplant Proc (2007) 2.76
Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng (2010) 2.66
Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol (2009) 2.60
Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells (2007) 2.54
Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood (2006) 2.49
Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia (2003) 2.39
Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum (2009) 2.38
Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med (2012) 2.19
Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol (2008) 2.17
Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant (2010) 2.00
Phenotypic changes of adult porcine mesenchymal stem cells induced by prolonged passaging in culture. J Cell Physiol (2005) 1.96
Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells (2009) 1.95
Identification of common pathways mediating differentiation of bone marrow- and adipose tissue-derived human mesenchymal stem cells into three mesenchymal lineages. Stem Cells (2006) 1.93
Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis (2010) 1.86
Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol (2012) 1.81
Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials. Exp Cell Res (2008) 1.79
Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther (2011) 1.76
Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol (2008) 1.72
Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation (2007) 1.72
Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. Transplantation (2008) 1.70
Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation (2006) 1.64
Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp Hematol (2008) 1.63
The International Registry on Hand and Composite Tissue Transplantation. Transplantation (2010) 1.59
Expanded adipose-derived stem cells suppress mixed lymphocyte reaction by secretion of prostaglandin E2. Tissue Eng (2007) 1.51
Different facets of aging in human mesenchymal stem cells. Tissue Eng Part B Rev (2010) 1.51
Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol (2012) 1.50
Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther (2010) 1.49
Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant (2009) 1.48
Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett (2007) 1.47
Relative antigenicity of components of a vascularized limb allograft. Plast Reconstr Surg (1991) 1.46
Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl Med (2013) 1.44
Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells. Clin Exp Immunol (2010) 1.41
Mesenchymal stromal cells and fibroblasts: a case of mistaken identity? Cytotherapy (2012) 1.33
Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg (2013) 1.30
Transplantation of bone marrow stromal cells for peripheral nerve repair. Exp Neurol (2007) 1.29
Adipose-derived stem cells stimulate regeneration of peripheral nerves: BDNF secreted by these cells promotes nerve healing and axon growth de novo. PLoS One (2011) 1.29
Migration of mesenchymal stem cells to heart allografts during chronic rejection. Transplantation (2003) 1.26
Marginal mass islet transplantation with autologous mesenchymal stem cells promotes long-term islet allograft survival and sustained normoglycemia. J Autoimmun (2009) 1.24
Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders. Ann N Y Acad Sci (2012) 1.22
HLA-G is a crucial immunosuppressive molecule secreted by adult human mesenchymal stem cells. Transplantation (2009) 1.20
Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant (2010) 1.20
Intravenous mesenchymal stem cells prevented rejection of allogeneic corneal transplants by aborting the early inflammatory response. Mol Ther (2012) 1.19
Mesenchymal stem cells prolong composite tissue allotransplant survival in a swine model. Transplantation (2009) 1.18
Human adipose tissue-derived mesenchymal stem cells induce explosive T-cell proliferation. Stem Cells Dev (2010) 1.16
Mesenchymal stem cell treatment for autoimmune diseases: a critical review. Biol Res (2012) 1.15
Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Arch Dermatol Res (2008) 1.14
Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat. Am J Transplant (2007) 1.13
Human adipose-derived mesenchymal stem cells systemically injected promote peripheral nerve regeneration in the mouse model of sciatic crush. Tissue Eng Part A (2012) 1.13
First human face transplantation: 5 years outcomes. Transplantation (2012) 1.13
Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats. Clin Immunol (2008) 1.13
Mesenchymal stem/stromal cells: a new ''cells as drugs'' paradigm. Efficacy and critical aspects in cell therapy. Curr Pharm Des (2013) 1.13
Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant (2012) 1.11
Modulation of immune response and T-cell regulation by donor adipose-derived stem cells in a rodent hind-limb allotransplant model. Plast Reconstr Surg (2011) 1.06
Mesenchymal stem cells together with mycophenolate mofetil inhibit antigen presenting cell and T cell infiltration into allogeneic heart grafts. Transpl Immunol (2010) 1.04
Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft. Transplant Proc (2006) 1.02
Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol (2012) 1.01
Human adipose tissue-derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children. Pediatr Transplant (2007) 1.00
Human mesenchymal stem cells and immunosuppressive drug interactions in allogeneic responses: an in vitro study using human cells. Transplant Proc (2009) 0.98
Role of mesenchymal stem cells in immunological rejection of organ transplantation. Stem Cell Rev (2009) 0.97
Long-term follow-up in composite tissue allotransplantation: in-depth study of five (hand and face) recipients. Am J Transplant (2011) 0.97
Mesenchymal stem cells as immunomodulators after liver transplantation. Liver Transpl (2009) 0.97
Paracrine effects of mesenchymal stem cells enhance vascular regeneration in ischemic murine skin. Microvasc Res (2012) 0.96
Rapamycin as an inhibitor of osteogenic differentiation in bone marrow-derived mesenchymal stem cells. J Orthop Sci (2007) 0.95
On the interactions between mesenchymal stem cells and regulatory T cells for immunomodulation in transplantation. Front Immunol (2012) 0.95
Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transpl Immunol (2011) 0.93
Prolongation of composite tissue allotransplant survival by treatment with bone marrow mesenchymal stem cells is correlated with T-cell regulation in a swine hind-limb model. Plast Reconstr Surg (2011) 0.91
Mesenchymal stem cells enhance the induction of mixed chimerism and tolerance to rat hind-limb allografts after bone marrow transplantation. J Surg Res (2008) 0.90
Immunomodulatory effects of mesenchymal stem cells derived from adipose tissues in a rat orthotopic liver transplantation model. Hepatobiliary Pancreat Dis Int (2008) 0.89
Combination of fibrin-agarose hydrogels and adipose-derived mesenchymal stem cells for peripheral nerve regeneration. J Neural Eng (2013) 0.88
Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease. Expert Opin Pharmacother (2008) 0.87
Transplantation of adipose-derived stem cells for peripheral nerve repair. Int J Mol Med (2011) 0.85
Immunomodulatory effects of bone marrow-derived mesenchymal stem cells in a swine hemi-facial allotransplantation model. PLoS One (2012) 0.83
Nonpharmacologic treatment of chronic graft-versus-host disease in children and adolescents. Biol Blood Marrow Transplant (2012) 0.81
Immunosuppressive function of bone marrow mesenchymal stem cells on acute rejection of liver allografts in rats. Transplant Proc (2009) 0.80
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol (2005) 7.80
Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature (2006) 5.49
Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol (2003) 5.07
Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol (2003) 4.66
TIM-4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation. Nat Immunol (2005) 3.00
TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur J Immunol (2009) 2.00
Outcomes of the first 2 American hand transplants at 8 and 6 years posttransplant. J Hand Surg Am (2008) 1.90
IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol (2011) 1.72
Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice. J Clin Invest (2008) 1.66
Tracking the immunoregulatory mechanisms active during allograft tolerance. J Immunol (2002) 1.50
A Statistical Comparative Assessment of Face and Hand Transplantation Outcomes to Determine Whether Either Meets the Standard of Care Threshold. Plast Reconstr Surg (2016) 1.41
Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts. Proc Natl Acad Sci U S A (2007) 1.35
Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J Immunol (2004) 1.33
Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg (2013) 1.30
Second report (1998-2006) of the International Registry of Hand and Composite Tissue Transplantation. Transpl Immunol (2007) 1.29
Anesthetic management in upper extremity transplantation: the Pittsburgh experience. Anesth Analg (2012) 1.25
Specificity of CD4+CD25+ regulatory T cell function in alloimmunity. J Immunol (2006) 1.19
Mesenchymal stem cells prolong composite tissue allotransplant survival in a swine model. Transplantation (2009) 1.18
Split tolerance to a composite tissue allograft in a swine model. Transplantation (2003) 1.18
Physiological mechanisms of regulating alloimmunity: cytokines, CTLA-4, CD25+ cells, and the alloreactive T cell clone size. J Immunol (2002) 1.12
Long-term acceptance of renal allografts following prenatal inoculation with adult bone marrow. Transplantation (2005) 1.11
New differentiation pathway for double-negative regulatory T cells that regulates the magnitude of immune responses. Blood (2006) 1.11
Roles of deletion and regulation in creating mixed chimerism and allograft tolerance using a nonlymphoablative irradiation-free protocol. J Immunol (2005) 1.08
On the intraoperative molecular status of renal allografts after vascular reperfusion and clinical outcomes. J Am Soc Nephrol (2005) 1.07
Mouse hind limb transplantation: a new composite tissue allotransplantation model using nonsuture supermicrosurgery. Transplantation (2010) 0.96
Regulation of T cell dependent immune responses by TIM family members. Philos Trans R Soc Lond B Biol Sci (2005) 0.96
Requirements for induction and maintenance of peripheral tolerance in stringent allograft models. Proc Natl Acad Sci U S A (2005) 0.96
Tim-1 signaling substitutes for conventional signal 1 and requires costimulation to induce T cell proliferation. J Immunol (2009) 0.96
Human Adipose-Derived Mesenchymal Stromal Cells May Promote Breast Cancer Progression and Metastatic Spread. Plast Reconstr Surg (2015) 0.93
A position statement in support of hand transplantation. J Hand Surg Am (2002) 0.92
Bystander central memory but not effector memory CD8+ T cells suppress allograft rejection. J Immunol (2008) 0.92
T regulatory cells and transplantation tolerance. Transplant Rev (Orlando) (2010) 0.90
Adipose- and Bone Marrow-Derived Mesenchymal Stem Cells Prolong Graft Survival in Vascularized Composite Allotransplantation. Transplantation (2015) 0.90
Hand transplantation. A future clinical option? Acta Orthop (2005) 0.88
Favoring the risk-benefit balance for upper extremity transplantation--the Pittsburgh Protocol. Hand Clin (2011) 0.88
Combined administration of a mutant TGF-beta1/Fc and rapamycin promotes induction of regulatory T cells and islet allograft tolerance. J Immunol (2010) 0.88
CTLA4 engagement is required for induction of murine liver transplant spontaneous tolerance. Am J Transplant (2005) 0.86
On CD28/CD40 ligand costimulation, common gamma-chain signals, and the alloimmune response. J Immunol (2002) 0.86
Composite tissue allotransplantation: hand transplantation and beyond. J Am Acad Orthop Surg (2010) 0.85
CD8(+) T cells resistant to costimulatory blockade are controlled by an antagonist interleukin-15/Fc protein. Transplantation (2006) 0.84
The complement dependent cytotoxicity (CDC) immune effector mechanism contributes to anti-CD154 induced immunosuppression. Transplantation (2002) 0.84
A Methodology for Determining Standard of Care Status for a New Surgical Procedure: Hand Transplantation. Plast Reconstr Surg (2016) 0.84
Review of the early diagnoses and assessment of rejection in vascularized composite allotransplantation. Clin Dev Immunol (2013) 0.83
Inhibition of T cell-dependent and RANKL-dependent osteoclastogenic processes associated with high levels of bone mass in interleukin-15 receptor-deficient mice. Arthritis Rheum (2010) 0.82
Clinical implementation of a procedure to prepare bone marrow cells from cadaveric vertebral bodies. Regen Med (2011) 0.82
A model for functional recovery and cortical reintegration after hemifacial composite tissue allotransplantation. Plast Reconstr Surg (2009) 0.81
Distinctive role of donor strain immature dendritic cells in the creation of allograft tolerance. Int Immunol (2006) 0.80
Composite tissue allotransplantation in chimeric hosts part II. A clinically relevant protocol to induce tolerance in a rat model. Transplantation (2003) 0.80
Hand allotransplantation. Semin Plast Surg (2010) 0.80
Clinical Considerations for Vascularized Composite Allotransplantation of the Eye. J Craniofac Surg (2016) 0.79
Site-specific immunosuppression in vascularized composite allotransplantation: prospects and potential. Clin Dev Immunol (2013) 0.79
Premise and promise of mesenchymal stem cell-based therapies in clinical vascularized composite allotransplantation. Curr Opin Organ Transplant (2015) 0.79
Proteomic analysis of the allograft response. Transplantation (2006) 0.79
Human facial allotransplantation: patient selection and pertinent considerations. J Craniofac Surg (2012) 0.78
The effect of chondroitinase on nerve regeneration following composite tissue allotransplantation. J Hand Surg Am (2011) 0.78
Are cultured mesenchymal stromal cells an option for immunomodulation in transplantation? Front Immunol (2013) 0.78
Functional outcomes following multiple acute rejections in experimental vascularized composite allotransplantation. Plast Reconstr Surg (2013) 0.77
Stable mixed hematopoietic chimerism permits tolerance of vascularized composite allografts across a full major histocompatibility mismatch in swine. Transpl Int (2014) 0.77
Hemiface allotransplantation in the mouse. Plast Reconstr Surg (2012) 0.77
Effects of an agonist interleukin-2/Fc fusion protein, a mutant antagonist interleukin-15/Fc fusion protein, and sirolimus on cardiac allograft survival in non-human primates. J Heart Lung Transplant (2012) 0.77
Th1 to Th2 immune deviation facilitates, but does not cause, islet allograft tolerance in mice. Cytokine (2010) 0.77
Surgical and technical aspects of hand transplantation: is it just another replant? Hand Clin (2011) 0.76
Low-dose immunosuppression in a rat hind-limb transplantation model. Transpl Int (2003) 0.76
RF System for Ultra-High Field Upper Extremity Imaging. Plast Reconstr Surg (2015) 0.76
A Critical Role for TGF-β/Fc and Nonlytic IL-2/Fc Fusion Proteins in Promoting Chimerism and Donor-Specific Tolerance. Transplantation (2017) 0.76
Blepharoplasty, laser in situ keratomileusis, and the corneal reflex arc. Plast Reconstr Surg (2008) 0.75
Molecular characterization and functional activity of an IL-15 antagonist MutIL-15/Fc human fusion protein. Mol Pharm (2013) 0.75
Heart allograft tolerance induced and maintained by vascularized hind-limb transplant in rats. Clin Dev Immunol (2013) 0.75
A rapid vascular anastomosis technique for hind-limb transplantation in rats. Plast Reconstr Surg (2010) 0.75
Adipogenesis for soft tissue reconstruction. Curr Opin Organ Transplant (2019) 0.75
Exploring Peripheral Nerve, Macro and Micro-Vasculature Imaging Applications at Ultra-High Field MRI. Plast Reconstr Surg (2015) 0.75
Effects of an interleukin-15 antagonist on systemic and skeletal alterations in mice with DSS-induced colitis. Am J Pathol (2013) 0.75
Targeting uncoupling protein-2 improves islet graft function. Cell Transplant (2010) 0.75
A Porcine Orthotopic Forelimb Vascularized Composite Allotransplantation Model: Technical Considerations and Translational Implications. Plast Reconstr Surg (2016) 0.75
Single Implantable FK506 Disk Prevents Rejection in Vascularized Composite Allotransplantation. Plast Reconstr Surg (2017) 0.75
Abstract 101: Intrathymic in Vivo Two-photon Microscopy Reveals the Interaction of Donor Bone Marrow-Derived Dendritic Cells and Host Thymocytes in a Model Of VCA Central Tolerance. Plast Reconstr Surg (2014) 0.75
Helping hands: caring for the upper extremity transplant patient. Crit Care Nurs Clin North Am (2011) 0.75
The Influence of Timing and Frequency of Adipose-derived Mesenchymal Stem Cell Therapy on Immunomodulation Outcomes after Vascularized Composite Allotransplantation. Transplantation (2016) 0.75
Differential inflammatory networks distinguish responses to bone marrow-derived vs. adipose-derived mesenchymal stem cell therapies in vascularized composite allotransplantation. J Trauma Acute Care Surg (2017) 0.75
Upper Extremity Ultra-High Field MR Imaging of Bilateral Hand Transplant Patient: Case Report (VCA). Plast Reconstr Surg (2015) 0.75
Development of an upper extremity transplant program. Hand Clin (2011) 0.75
Optimizing Outcomes in Pharyngoesophageal Reconstruction and Neck Resurfacing: 10-Year Experience of 294 Cases. Plast Reconstr Surg (2017) 0.75
Plate exposure after anterolateral thigh free-flap reconstruction in head and neck cancer patients with composite mandibular defects. Ann Surg Oncol (2015) 0.75